IC50: 0.4 μM (CDA)[1]
Cedazuridine (E7727) (Compound 7a) is an orally active cytidine deaminase (CDA) inhibitor with an IC50 value of 0.4 μM. Cedazuridine can be used for cancer research[1].
Cedazuridine (Compound 7a) exhibits superior acid stability[1].
Cedazuridine (0-10 μM; 72 h) does not enhance effects of AZA (5-Azacytidine, HY-10586) in growth inhibition of AML cell lines[2].
Cedazuridine (3 mg/kg; p.o.; daily for 7 days) in combination with 2.5 mg/kg AZA shows tumor regression in mice MOLM-13 CDX and PDX models[2].
| Animal Model: | Female NSGS mice, 6-8 weeks old, human cell line-derived (CDX) and primary patient-derived xenograft (PDX) models[2] |
| Dosage: | 3 mg/kg |
| Administration: | Oral administration, in combination with 2.5 mg/kg AZA, daily for 7 days |
| Result: | Led to reduction of leukemic expansion in combination with AZA in a cell line-derived xenograft transplantation, and exhibited preliminary safety and efcacy in a primary AML PDX model. |
| Animal Model: | NSGS male mice[2] |
| Dosage: | 1, 3, 10 and 30 mg/kg |
| Administration: | Oral, in combination with 2.5 mg/kg AZA (Pharmacokinetic Studies) |
| Result: | Dose-dependently increased the AUC of oral AZA and in comparison to dosing of standard i.p. AZA. |